The operation concerns RDI activities in the field of medical devices/technologies. The investment includes costs related to R&D, clinical trials, regulatory approval and pre-launch marketing of new medical devices. The devices are developed in separate, offshore legal entities that are majority-owned or otherwise controlled by the promoter, who is also actively involved in the strategic management and supervision of the companies. The medical devices / technologies are aimed at the treatment of different diseases in the fields of cardiovascular, stroke rehabilitation and diabetes as well as nuclear imaging and cryopreservation technology (e.g. freeze-drying of cells).
Objectives
Aging population and the increase of incidences of certain major disease indications such as cardiovascular diseases, cancer, diabetes and obesity all will further lead to an increased demand for innovative products. All products being developed by the portfolio companies would potentially address a medical unmet need and would improve the quality of life of patients.
Comments
Sector(s)
Industry
Proposed EIB finance (Approximate amount)
EUR 30 million
Total cost (Approximate amount)
EUR 230 million
Environmental aspects
The R&D activities encompassed within this project will not materially change current R&D practices and will be carried out within existing facilities, mostly in Israel and Europe making use of existing laboratories, pilot plants, clinical centers etc, thus not requiring an EIA according to the EU Directive 97/11 as amended by Directive 2003/35. Compliance of R&D activities with relevant EU and local environmental legislation as well as full environmental details will be verified during appraisal.
Procurement
The promoter’s portfolio companies are private companies not operating in the utilities sector, and are thus not covered by EU Directives on procurement. However, the nature of the procurement procedures will be verified during appraisal and checked for each company in the portfolio.
Status
Signed
-
25/11/2008.
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. Therefore data provided on this page is indicative and cannot be considered to represent official EIB Policy (see also the Explanatory notes).
The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities. Enquiries and comments regarding the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, EIB can also be contacted through its external offices.
Queries regarding details of a specific project, in particular when EIB loan is under appraisal, should be preferably addressed directly to project promoters.
Any complaint regarding alleged maladministration can be lodged to EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.
Zero-tolerance against fraud and corruption
The EIB has a zero-tolerance policy on fraud or corruption. To report allegations of fraud or corruption in EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential, and are handled in line with EIB investigation procedures and the Anti-Fraud Policy.
The EIB is committed to achieving the highest possible level of transparency. The EIB Transparency Policy sets out how EIB discloses information and consults with its stakeholders so as to promote better awareness and understanding of its strategies, policies and operations.
